Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients

The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the last decades, with an improved median survival of 8-10 years. This study aimed to evaluate the bortezomib, cyclophosphamide and dexamethasone (VCD) regimen versus bortezomib and dexamethasone (VD) regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciftciler, Rafiye, Goker, Hakan, Buyukasik, Yahya, Sayınalp, Nilgun, Haznedaroglu, Ibrahim C., Aksu, Salih, Ozcebe, Osman, Demiroglu, Haluk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212206/
https://www.ncbi.nlm.nih.gov/pubmed/32399162
http://dx.doi.org/10.4081/hr.2020.8267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212206/
https://www.ncbi.nlm.nih.gov/pubmed/32399162
http://dx.doi.org/10.4081/hr.2020.8267

Ejemplares similares